Evidence map›Paper›PMID 29637385›Full record

ReviewCurrent hypertension reports2018

Blood Pressure Goals in Acute Stroke-How Low Do You Go?

Iryna Lobanova, Adnan I Qureshi

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03655964 (Olmesartan Versus Nebivolol in Management of Hypertension in Acute Ischemic Stroke), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03655964 phase2completednot on this map

Olmesartan Versus Nebivolol in Management of Hypertension in Acute Ischemic Stroke

TypeinterventionalSponsorAristotle University Of ThessalonikiRan2018 to 2019Enrolled60ConditionsStroke, IschemicArmsOlmesartan, Nebivolol, No antihypertensive treatment
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Iryna LobanovaZeenat Qureshi Stroke Institute, St. Cloud, MN, USA. lobanovanmu@gmail.com.
Adnan I QureshiZeenat Qureshi Stroke Institute, St. Cloud, MN, USA.
CentraCare Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewElevations in systolic blood pressure (BP) greater than 140 mmHg are reported in the majority (75%) of patients with acute ischemic stroke and in 80% of patients with acute intracerebral hemorrhages (ICH). This paper summarizes and updates the current knowledge regarding the proper management strategy for elevated BP in patients with acute stroke. Recent studies have generally showed a neutral effect of BP reduction on clinical outcomes among acute ischemic stroke patients. Thus, because of the lack of convincing evidence from clinical trials, aggressive BP reduction in patients presenting with acute ischemic stroke is currently not recommended. Although in patients treated with intravenous tissue plasminogen activator, guidelines are recommending BP < 180/105 mmHg but currently, the optimal BP management after reperfusion therapy still remains unclear. In acute ICH, the evidence from randomized clinical trials supports the immediate BP lowering targeting systolic BP to 140 mmHg, which is now recommended by guidelines.

Indexed as

Antihypertensive AgentsBlood PressureCerebral HemorrhageHumansHypertensionPatient Care PlanningRandomized Controlled Trials as TopicStrokeTissue Plasminogen ActivatorAntihypertensive AgentsTissue Plasminogen ActivatorBlood pressureIntracerebral hemorrhageIschemic stroke

Identifiers

PMID29637385
OpenAlexW2797447405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.